Oncology Nursing Drug Handbook | Mobile App


Oncology Nursing Drug Handbook

Author(s):

Publisher: Jones and Bartlett Publishers, Inc.

ISBN 10: 1284171329

ISBN 13: 978-1284171327



Description At A Glance

Created especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential resource provides valuable information on effective symptom management, patient education, and chemotherapy administration.

Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.

Key Features

  • Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
  • Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
  • Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
  • Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
  • New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)
{oncondh21:3492}

Your Voice

By Anthony Arthur
It is your best service to consumers that makes the consumers come back to you. Customer service is very effective. My tip of the hat to you folks.

Share Via

KEEP IN TOUCH

     

Subscribe

Copyright © 2020. All rights reserved. Skyscape® is the registered trademark of Skyscape Medpresso, Inc.
All other trademarks, service marks and registrations are the intellectual properties of their respective owners.